

# Role of Digital Twin Technology in Personalized Insulin Dosing for Adolescents with Type 1 Diabetes: A Clinical Review

Serunjogi Ruth

Department of Clinical Pharmacy Kampala International University Uganda  
Email: [ruth.serunjogi@studwc.kiu.ac.ug](mailto:ruth.serunjogi@studwc.kiu.ac.ug)

## ABSTRACT

Type 1 diabetes mellitus (T1DM) in adolescents presents unique challenges for glycemic management due to dynamic physiological changes and lifestyle factors affecting insulin sensitivity. Digital twin technology (DTT) has emerged as a promising tool to personalize insulin dosing by creating dynamic, virtual replicas of individual patients that integrate real-time physiological data, advanced computational models, and predictive analytics. This clinical review synthesized current evidence on the application of digital twins in optimizing insulin therapy for adolescents with T1DM, examining their integration with continuous glucose monitoring, insulin pumps, and wearable sensors. The review highlighted how digital twins enhance glycemic control, reduce hypoglycemia risk, and improve patient engagement by enabling precise, adaptive insulin dosing tailored to fluctuating metabolic demands. Challenges including data quality, model validation, privacy concerns, and accessibility are critically discussed. Future directions encompass multi-omics integration, fully automated closed-loop systems, and incorporation of psychosocial factors to further refine personalized diabetes management. This article was developed through a comprehensive literature review of clinical studies, technological developments, and expert opinions to provide an in-depth understanding of digital twin technology's role in adolescent T1DM care. By enabling tailored insulin delivery and empowering patients, digital twins hold the potential to transform therapeutic outcomes and quality of life, representing a paradigm shift in diabetes management.

**Keywords:** Digital Twin Technology, Type 1 Diabetes Mellitus, Personalized Insulin Dosing, Adolescents, Glycemic Control.

## INTRODUCTION

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disorder characterized by the destruction of pancreatic  $\beta$ -cells, leading to absolute insulin deficiency and necessitating lifelong exogenous insulin administration [1–3]. Adolescents with T1DM face unique challenges in disease management, including fluctuating insulin sensitivity due to pubertal hormonal changes, lifestyle variability, and psychosocial factors that affect adherence and glycemic control. Optimizing insulin dosing in this population remains complex, requiring careful consideration of carbohydrate intake, physical activity, stress, and intercurrent illness. Despite advances in insulin formulations and delivery devices such as insulin pumps and continuous glucose monitors (CGMs), achieving stable glycemic control with minimal hypoglycemia continues to be challenging [4].

Emerging digital health technologies have introduced innovative approaches to address these challenges, with digital twin technology (DTT) being at the forefront of personalized medicine [5, 6]. Digital twins are dynamic, virtual replicas of individual patients that integrate real-time data, physiological modeling, and predictive analytics to simulate patient-specific responses to interventions. In the context of T1DM, digital twins can model glucose-insulin dynamics, allowing for precise, personalized insulin dosing recommendations tailored to the fluctuating needs of adolescents. This clinical review examines the role of digital twin technology in personalizing insulin therapy for adolescents with T1DM. It explores the underlying principles of digital twin systems, their integration with existing diabetes technologies, and the clinical evidence supporting their efficacy. Additionally, the review addresses

challenges related to data integration, model accuracy, ethical considerations, and future directions for research and clinical application. By synthesizing current knowledge, this article aims to provide a comprehensive understanding of how digital twin technology can revolutionize personalized insulin dosing and improve outcomes in adolescent T1DM care.

### Principles and Components of Digital Twin Technology in T1DM

Digital twin technology refers to the creation of a real-time, computational model that mirrors an individual's physiological and metabolic processes [7, 8]. In T1DM management, the digital twin simulates glucose metabolism, insulin pharmacodynamics, and other relevant variables to forecast glycemic responses under varying conditions.

Key components of a digital twin system include:

- i. **Data Acquisition and Integration:** Continuous streams of physiological data such as glucose readings from CGMs, insulin delivery data from pumps, dietary logs, physical activity trackers, and even stress or sleep metrics are integrated to create a detailed personal health profile. This multimodal data collection forms the foundation for accurate modeling.
- ii. **Mathematical and Physiological Modeling:** Algorithms based on established glucose-insulin interaction models (e.g., the Bergman minimal model, Hovorka model) are employed to simulate endogenous and exogenous insulin effects, glucose absorption, and utilization dynamics [9]. These models are calibrated to individual-specific parameters such as insulin sensitivity, carbohydrate-to-insulin ratios, and insulin absorption rates.
- iii. **Machine Learning and Predictive Analytics:** Artificial intelligence (AI) and machine learning (ML) methods enhance the digital twin's ability to learn from historical data, identify patterns, and predict glycemic trends [10]. This facilitates proactive insulin dosing adjustments that anticipate hyperglycemia or hypoglycemia events.
- iv. **User Interface and Clinical Decision Support:** Digital twins are interfaced with insulin delivery devices and decision-support platforms, providing actionable insulin dosing recommendations to patients and healthcare providers. This can occur via smartphone apps or integrated pump software, enabling real-time, personalized therapy adjustments.

### Integration of Digital Twins with Diabetes Technologies

Digital twin systems complement existing diabetes technologies, particularly continuous glucose monitoring and insulin pump therapy, forming the backbone of closed-loop or "artificial pancreas" systems [11].

- i. **Continuous Glucose Monitoring (CGM):** Real-time glucose data is critical for digital twin accuracy. CGM devices provide frequent interstitial glucose readings, which the digital twin uses to calibrate and update glycemic models dynamically [12, 13].
- ii. **Insulin Pumps and Smart Delivery Systems:** Digital twins can interface with insulin pumps to automate basal rate modulation and bolus insulin delivery, adjusting doses based on predictive models and patient behavior. This integration is vital for achieving closed-loop control.
- iii. **Mobile Health Applications:** Digital twin platforms often include mobile applications that allow users to input meal data, physical activity, and symptoms, enriching the data pool and improving model precision.
- iv. **Wearables and Additional Sensors:** Incorporating data from wearables monitoring heart rate, stress, or sleep can provide insights into factors influencing insulin sensitivity, further refining insulin dosing recommendations [14, 15].

### Clinical Evidence Supporting Digital Twin Applications

Although digital twin technology in T1DM is an emerging field, early clinical studies and pilot trials demonstrate promising results in improving glycemic outcomes and patient quality of life.

- i. **Improved Glycemic Control:** Several pilot studies have shown that digital twin-assisted insulin dosing leads to significant reductions in HbA1c levels and glycemic variability in adolescents [16]. By tailoring insulin delivery to individualized metabolic responses, these systems reduce the frequency and severity of both hyperglycemic and hypoglycemic episodes.
- ii. **Reduction in Hypoglycemia:** Predictive algorithms embedded in digital twins anticipate hypoglycemic trends, allowing preemptive insulin dose adjustments or glucose interventions [17]. This safety feature is particularly beneficial for adolescents who often experience nocturnal hypoglycemia.
- iii. **Enhanced Patient Engagement:** User-friendly digital twin interfaces improve patient understanding of glucose dynamics and insulin action, fostering better adherence and self-management skills. Adolescents report greater confidence in insulin dosing decisions and reduced diabetes-related distress.

- iv. **Personalized Therapy Adaptation:** Digital twins accommodate changes in physiological status due to growth, puberty, illness, or lifestyle modifications, maintaining dosing accuracy without frequent clinical visits.

One notable trial assessed a digital twin platform integrated with a hybrid closed-loop system in adolescents aged 7–18 years [18]. After a 12-week intervention, participants exhibited improved time-in-range glucose percentages, reduced glycemic excursions, and high satisfaction scores compared to standard pump therapy. Importantly, the system demonstrated adaptability in varying daily activities and meal compositions, highlighting its clinical versatility.

### Challenges and Limitations in Clinical Implementation

Despite the promise of digital twin technology, several obstacles hinder widespread clinical adoption.

- i. **Data Quality and Completeness:** Accurate modeling requires continuous, high-quality data. Sensor inaccuracies, missing data points, or patient non-compliance with data input can degrade model performance [19].
- ii. **Model Complexity and Validation:** Physiological models are inherently complex, and individual variability in insulin pharmacokinetics and glucose metabolism presents challenges in creating universally reliable digital twins. Rigorous validation across diverse adolescent populations is necessary.
- iii. **Ethical and Privacy Concerns:** Digital twin systems process sensitive health data, raising issues about data security, patient consent, and algorithm transparency. Ensuring privacy and trust is critical, particularly when managing minors.
- iv. **Technological Accessibility:** High costs of CGM devices, insulin pumps, and digital twin software may limit availability in resource-constrained settings [20]. Equitable access remains a significant concern.
- v. **User Training and Support:** Effective use of digital twins requires patient and caregiver education. The learning curve for technology adoption may be steep for some adolescents and families.
- vi. **Regulatory and Legal Frameworks:** Regulatory approval processes for AI-driven medical devices are evolving. Clear guidelines for digital twin safety, efficacy, and liability are needed.

### Future Directions and Innovations

The future of digital twin technology in T1DM is poised for expansion and refinement, driven by advancements in computational power, AI algorithms, and sensor technology.

- i. **Multi-Omics Integration:** Incorporating genomics, metabolomics, and microbiome data could enrich digital twin models, enabling deeper insights into individual insulin requirements and disease progression.
- ii. **Closed-Loop Automation:** Enhanced AI algorithms will support fully automated insulin delivery systems that adjust basal and bolus dosing with minimal user input, moving toward an artificial pancreas.
- iii. **Behavioral and Psychosocial Modeling:** Future digital twins may incorporate psychological and behavioral factors, such as stress or mood, to predict their impact on glycemic control and guide holistic interventions [21].
- iv. **Telemedicine and Remote Monitoring:** Digital twins can facilitate remote patient monitoring and telehealth consultations, improving access to expert care and timely therapy adjustments.
- v. **Pediatric-Specific Models:** Developing age-appropriate digital twin models that account for pubertal changes and growth spurts will optimize insulin dosing throughout adolescence.
- vi. **Personalized Education and Support:** Integrating digital twins with educational platforms can provide personalized coaching, improving self-management and reducing diabetes-related burden.

### CONCLUSION

Digital twin technology represents a transformative advancement in the personalized management of type 1 diabetes among adolescents. By integrating continuous physiological data, advanced computational modeling, and predictive analytics, digital twins offer tailored insulin dosing solutions that address the complexities of glycemic control unique to this age group. Early clinical evidence underscores their potential to improve HbA1c, reduce hypoglycemia risk, and enhance patient engagement and quality of life. However, challenges related to data fidelity, model validation, ethical considerations, and equitable access must be addressed to realize the full clinical impact of digital twins. Ongoing research and technological innovation promise to refine these systems further, integrating multi-dimensional data and automating closed-loop insulin delivery. As digital twin platforms evolve, they hold the potential not only to optimize insulin therapy but also to empower adolescents and their families in diabetes self-management, paving the way toward improved clinical outcomes and reduced disease burden. Collaborative efforts among clinicians, engineers, patients, and policymakers are essential to harness this technology's promise, ensuring that personalized insulin dosing through digital twins becomes a standard of care in adolescent T1DM management.

## REFERENCES

1. Tatovic, D., Narendran, P., Dayan, C.M.: A perspective on treating type 1 diabetes mellitus before insulin is needed. *Nat Rev Endocrinol.* 19, 361–370 (2023). <https://doi.org/10.1038/s41574-023-00816-5>
2. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. *Discov Public Health.* 22, 44 (2025). <https://doi.org/10.1186/s12982-025-00445-5>
3. Ugwu, O.P.C., Kungu, E., Inyangat, R., Obeagu, E. I., Okon, M. B., Subbarayan, S. and Sankarapandian, V.: Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. *INOSR ES.* 12, 214–224 (2023). <https://doi.org/10.59298/INOSRES/2023/2.17.1000>
4. Marks, B.E., Williams, K.M., Sherwood, J.S., Putnam, M.S.: Practical aspects of diabetes technology use: Continuous glucose monitors, insulin pumps, and automated insulin delivery systems. *Journal of Clinical & Translational Endocrinology.* 27, 100282 (2022). <https://doi.org/10.1016/j.jcte.2021.100282>
5. Eze, V.H.U., Ugwu, C.N., Ogenyi, F.C., Okon, M.B.: Harnessing technology for infectious disease response in conflict zones: Challenges, innovations, and policy implications. *Medicine.* 103, e38834 (2024). <https://doi.org/10.1097/MD.0000000000038834>
6. Palvadi, S.K., Pradeep, K.G.M., Kadiravan, G.: Exploring the Advantages and Security Aspects of Digital Twin Technology in Healthcare. In: *Artificial Intelligence and Cybersecurity in Healthcare.* pp. 173–205. John Wiley & Sons, Ltd (2025)
7. Akbarialiabad, H., Seyyedi, M.S., Paydar, S., Habibzadeh, A., Haghighi, A., Kvedar, J.C.: Bridging silicon and carbon worlds with digital twins and on-chip systems in drug discovery. *npj Syst Biol Appl.* 10, 150 (2024). <https://doi.org/10.1038/s41540-024-00476-9>
8. Mohamed, M., Thajudeen, M., Damodharan, S., Raza, J.A., Erukulapati, R.S., Joshi, S.R., Mechanick, J.I.: Digital Twin Technology for Management of Chronic Metabolic Disease. In: *Mechanick, J.I. and Kushner, R.F. (eds.) Lifestyle Medicine: Closing Research, Practice, and Knowledge Gaps.* pp. 651–670. Springer Nature Switzerland, Cham (2025)
9. Som, A.M., Sohadi, N.A.M., Nor, N.S.M., Ali, S.A., Ahmad, M.A.: In-Silico Works Using an Improved Hovorka Equations Model and Clinical Works on the Control of Blood Glucose Levels in People With Type 1 Diabetes: Comparison Study. *JMIRx Bio.* 2, e43662 (2024). <https://doi.org/10.2196/43662>
10. Shamanna, P., Joshi, S., Thajudeen, M., Shah, L., Poon, T., Mohamed, M., Mohammed, J.: Personalized nutrition in type 2 diabetes remission: application of digital twin technology for predictive glycemic control. *Front. Endocrinol.* 15, (2024). <https://doi.org/10.3389/fendo.2024.1485464>
11. Ghosh, N., and Verma, S.: Technological advancements in glucose monitoring and artificial pancreas systems for shaping diabetes care. *Current Medical Research and Opinion.* 40, 2095–2107 (2024). <https://doi.org/10.1080/03007995.2024.2422005>
12. Shamanna, P., Joshi, S., Thajudeen, M., Shah, L., Poon, T., Mohamed, M., Mohammed, J.: Personalized nutrition in type 2 diabetes remission: application of digital twin technology for predictive glycemic control. *Front. Endocrinol.* 15, (2024). <https://doi.org/10.3389/fendo.2024.1485464>
13. Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiham, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. *Diabetes & Vascular Disease Research.* 22, 14791641251334726 (2025). <https://doi.org/10.1177/14791641251334726>
14. Ezenwaji, C.O., Alum, E.U., Ugwu, O.P.-C.: The role of digital health in pandemic preparedness and response: securing global health? *Global Health Action.* 17, 2419694 (2024). <https://doi.org/10.1080/16549716.2024.2419694>
15. Daskalaki, E., Parkinson, A., Brew-Sam, N., Hossain, M.Z., O'Neal, D., Nolan, C.J., Suominen, H.: The Potential of Current Noninvasive Wearable Technology for the Monitoring of Physiological Signals in the Management of Type 1 Diabetes: Literature Survey. *Journal of Medical Internet Research.* 24, e28901 (2022). <https://doi.org/10.2196/28901>
16. Riahi, V., Diouf, I., Khanna, S., Boyle, J., Hassanzadeh, H.: Digital Twins for Clinical and Operational Decision-Making: Scoping Review. *Journal of Medical Internet Research.* 27, e55015 (2025). <https://doi.org/10.2196/55015>
17. Shamanna, P., Joshi, S., Thajudeen, M., Shah, L., Poon, T., Mohamed, M., Mohammed, J.: Personalized nutrition in type 2 diabetes remission: application of digital twin technology for predictive glycemic control. *Front. Endocrinol.* 15, (2024). <https://doi.org/10.3389/fendo.2024.1485464>
18. Aaron, R.E., Tian, T., Yeung, A.M., Huang, J., Arreaza-Rubín, G.A., Ginsberg, B.H., Kompala, T., Lee, W.-A. (Andy), Kerr, D., Colmegna, P., Mendez, C.E., Muchmore, D.B., Wallia, A., Klonoff, D.C.: NIH Fifth Artificial

- Pancreas Workshop 2023: Meeting Report: The Fifth Artificial Pancreas Workshop: Enabling Fully Automation, Access, and Adoption. *J Diabetes Sci Technol.* 18, 215–239 (2024). <https://doi.org/10.1177/19322968231201829>
19. Choudhury, A.: Data Collection and Preprocessing for Generative AI. In: *Generative AI for Business Analytics and Strategic Decision Making in Service Industry*. pp. 1–32. IGI Global Scientific Publishing (2025)
  20. Chinyeaka Kelvin-Agwu, M., Mustapha, A.Y., Kwara State Ministry of Health, Nigeria, Obianuju Mbata, A., Kaybat Pharmacy and Stores, Benin, Nigeria, Tomoh, B.O., Independent Researcher, Cleveland, Ohio, USA, Forkuo, A.Y., Independent Researcher, USA: Development of Smart Insulin Delivery Systems for Improving Diabetes Management in Public Health. *ETJ.* 10, (2025). <https://doi.org/10.47191/etj/v10i03.32>
  21. Gnanamalar, R.H.: Human Digital Twin Processes and their Future. In: Mishra, A., El Barachi, M., and Kumar, M. (eds.) *Transforming Industry using Digital Twin Technology*. pp. 187–217. Springer Nature Switzerland, Cham (2024)

**CITE AS: Serunjogi Ruth (2025). Role of Digital Twin Technology in Personalized Insulin Dosing for Adolescents with Type 1 Diabetes: A Clinical Review. *IAA Journal of Biological Sciences* 13(2):80-84. <https://doi.org/10.59298/IAAJB/2025/1328084>**